Massive PE study tests new clot-buster on 20,000 patients
NCT ID NCT07245927
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 24 times
Summary
This study is tracking how safe and effective a drug called non-immunogenic staphylokinase is for people with a massive blood clot in the lungs (pulmonary embolism). Researchers will follow 20,000 adults who receive this clot-busting medicine in regular hospital care. The main goal is to see how many patients survive during their hospital stay and over the next 30 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM ACUTE MASSIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
E.I. Chazov National Medical Research Center of Cardiology
RECRUITINGMoscow, 121552, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.